Irritable Bowel Syndrome With Constipation (ibs C) Therapeutics
1. Ibsrela patent expiration
Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8969377 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(3 years from now) | |
| US12016856 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(3 years from now) | |
| US8541448 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Aug, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9006281 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
May, 2030
(4 years from now) | |
| US9408840 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder |
Dec, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 12 September, 2019
Dosage: TABLET
More Information on Dosage
IBSRELA family patents
2. Linzess patent expiration
Treatment: Method of treating chronic idiopathic constipation in adult patients.; Method of treating of irritable bowel syndrome with constipation (ibs-c) in pediatric patients 7 years of age and older; Method o...
LINZESS's oppositions filed in EPO
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7304036 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Aug, 2026
(7 months from now) | |
| US7745409 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| US7704947 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| US8080526 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| US7371727 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8110553 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| US8933030 | ABBVIE | Treatments for gastrointestinal disorders |
Feb, 2031
(5 years from now) | |
| US8748573 | ABBVIE | Formulations comprising linaclotide |
Oct, 2031
(5 years from now) | |
| US9708371 | ABBVIE | Treatments for gastrointestinal disorders |
Aug, 2033
(7 years from now) | |
| US10702576 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(5 years from now) | |
| US8802628 | ABBVIE | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration |
Oct, 2031
(5 years from now) | |
| US10675325 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(5 years from now) | |
|
US8802628 (Pediatric) | ABBVIE | NA |
Apr, 2032
(6 years from now) | |
|
US7304036 (Pediatric) | ABBVIE | NA |
Feb, 2027
(1 year, 1 month from now) | |
|
US8748573 (Pediatric) | ABBVIE | NA |
Apr, 2032
(6 years from now) | |
|
US9708371 (Pediatric) | ABBVIE | NA |
Feb, 2034
(8 years from now) | |
|
US8933030 (Pediatric) | ABBVIE | NA |
Aug, 2031
(5 years from now) | |
|
US10675325 (Pediatric) | ABBVIE | NA |
Feb, 2032
(6 years from now) | |
|
US10702576 (Pediatric) | ABBVIE | NA |
Feb, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2017 |
| New Strength(NS) | Jan 25, 2020 |
| New Indication(I-921) | Jun 12, 2026 |
Drugs and Companies using LINACLOTIDE ingredient
NCE-1 date: 30 August, 2016
Market Authorisation Date: 25 January, 2017
Dosage: CAPSULE
How can I launch a generic of LINZESS before it's drug patent expiration?
More Information on Dosage
LINZESS family patents